Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scone study seeks to unlock Fiber's secret powers against blood sugar spikes

NCT ID NCT07420023

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how adding different types and combinations of dietary fiber to scones affects blood sugar, feelings of fullness, and gut bacteria. Overweight but otherwise healthy adults will eat seven different fiber-enriched scones over several days. Researchers will track blood sugar continuously and measure fullness and gut bacteria changes. The goal is to learn how fibers interact in processed foods to improve health, which could lead to better food design for preventing type 2 diabetes and heart disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dietary fiber (added to scones)
What this could lead to
If successful, this could help food makers design processed foods that better control blood sugar and increase fullness, potentially reducing risk for type 2 diabetes and heart disease.
What could go wrong
This is a small, early-stage study with only 24 people, so results may not apply to everyone. The fibers are tested in scones, a specific food, so findings might not translate to other foods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be willing and able to give written informed consent. * Be between 18 and 45 years of age. * Have a BMI of =25\<30kg/m2(overweight). * Have a waist circumference of \>94cm for a male, \>80cm for a female (increased risk of metabolic syndrome). * Have had a stable body weight (\<5% change over the past three months). * Be in general good health as determined by the investigator through interview and vital signs (blood pressure, pulse, temperature). Systolic blood pressure less than 160mm Hg and diastolic blood pressure less than 100 mm Hg (defined as Hypertension stage 2). * Be willing to avoid consuming dietary supplements (at the discretion of the investigator), prebiotics, probiotics, or fibre-rich supplements within four weeks before the baseline visit, and until the end of the study. * Be willing to avoid vigorous physical activities on the interventional days (defined as any physical activity that is planned to achieve a fitness goal). * Be willing to consume the investigational food products and menu plan daily for the duration of the study. Exclusion Criteria: * Pregnant, lactating, or post-menopausal women, or women who are planning to become pregnant over the study period. * Have had antibiotic treatment within three months before baseline. * Are taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk, or confound the interpretation of study results; to include anti-inflammatory drugs, H2 blockers, antacids, proton pump inhibitors, anti-hypertensive medications, corticosteroids, laxatives, enemas, antibiotics, anti-coagulants, and immunosuppressant medication. Participants should have a wash-out period of at least two weeks for each of these medications except for antibiotics, which should not have been taken in the previous three months. Participants taking proton pump inhibitors and medications for chronic conditions (e.g., anti-hypertensive medication) will be allowed into the study if the dose has been stable for at least two months before the study baseline visit. * Have a history or indication of drug and/or alcohol abuse at the time of enrolment. * Have a habitual alcohol consumption of \>2 alcoholic beverages/day (\>28g ethanol daily). * Follow a vegetarian or vegan diet. * Have a typical fibre intake of \>30g per day. * Have experienced major dietary changes within three months before the study baseline. * Plan major lifestyle changes (diet, physical activity, or travel) during the study period. * Have a clinically diagnosed eating disorder. * Have a food allergy or intolerance that would preclude study product intake (for example, eggs, gluten, nuts, milk, or any other food allergy or intolerance). * Have an active gastrointestinal disorder or previous gastrointestinal surgery. * Have a significant active and medically-diagnosed acute or chronic co-existing illness including: metabolic, psychiatric, cardiovascular, endocrinological, immunological condition, gastrointestinal disease or any other condition which contraindicates, in the investigator's judgement, entry to the study (such as, diarrhoea, Crohn's disease, ulcerative colitis, IBS, diverticulosis, stomach or duodenal ulcers, hepatitis A/B/C, HIV, cancer, diabetes etc) or a significant history of such diseases. * Are severely immunocompromised (e.g., HIV positive, transplant patient, on anti-rejection medications, on a steroid for \>30 days, or chemotherapy or radiotherapy within the last 12 months). * Have a malignant disease or concomitant end-stage organ disease. * Have symptomatic respiratory or cardiac illness. * Experience alarm features such as sudden weight loss, rectal bleeding, a recent change in bowel habits, or significant abdominal pain within three months before baseline. * Individuals who, in the opinion of the investigator, are poor attendees or unlikely for any reason to be able to comply with the study protocol. * Are receiving treatment involving experimental drugs. * If the participant has been in a recent experimental trial, these must have been completed not less than 30 days before this study. * Individuals who regularly undertake rigorous exercise. * Individuals who smoke or vape.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic diseases, type 2 diabetes, cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • University College Cork

    RECRUITING

    Cork, Ireland

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.